Filtered By:
Condition: Heart Attack
Vaccination: Vaccines
This page shows you your search results in order of date. This is page number 3.
Order by Relevance | Date
Total 175 results found since Jan 2013.
The trends and determinants of seasonal influenza vaccination after cardiovascular events in Canada: a repeated, pan-Canadian, cross-sectional study
CONCLUSION: Influenza vaccination is still at less than the recommended level in patients with CVD. Future research should consider the impact of interventions to improve vaccination uptake in this population.PMID:36794825 | DOI:10.24095/hpcdp.43.2.04
Source: Health Promotion and Chronic Disease Prevention in Canada - February 16, 2023 Category: International Medicine & Public Health Authors: Hanna Cho Sherilyn J D Houle Wasem Alsabbagh Source Type: research
Janssen Data at ASCO GU Support Ambition to Transform Treatment of Prostate and Bladder Cancer Through Precision Medicine and Early Intervention
RARITAN, N.J., February 13, 2023 – The Janssen Pharmaceutical Companies of Johnson & Johnson today announced plans to present more than 20 abstracts featuring seven oncology therapies from its robust portfolio and pipeline at the annual American Society of Clinical Oncology (ASCO) Genitourinary (GU) Cancers Symposium, taking place in San Francisco on February 16-18. Building on more than a decade of leadership in the development of medicines for people diagnosed with GU cancers, Janssen will present data demonstrating its ambition to advance patient-centered treatment through precision medicine, real-world evidence a...
Source: Johnson and Johnson - February 13, 2023 Category: Pharmaceuticals Tags: Latest News Source Type: news
Inactivated whole-virion SARS-CoV-2 vaccines and long-term clinical outcomes in patients with coronary atherosclerosis disease in China: a prospective cohort study
CONCLUSIONS: Our results indicated no evidence of an increased ischemic or bleeding risk after vaccination with inactivated SARS-CoV-2 vaccine among Chinese patients with CAD, with limited statistical power.PMID:36756815 | DOI:10.1093/cvr/cvad031
Source: Atherosclerosis - February 9, 2023 Category: Cardiology Authors: Huajie Xu Jiaojiao Zheng Xin Zhao Qi Zhou Bing Fan Hongyi Wu Si Zhang Junbo Ge Source Type: research
Herpes zoster and long-term vascular risk: a retrospective cohort study
Sci Rep. 2023 Feb 9;13(1):2364. doi: 10.1038/s41598-023-29667-w.ABSTRACTHerpes zoster (HZ) represents a serious health problem in the general population due to its abundance and complications. Stroke and acute myocardial infarction are well-documented short-term complications of HZ, primarily due to vasculopathy in the cerebral and coronary arteries. However, no major study to date has specifically demonstrated that HZ is a long-term risk factor for all Major Adverse Cardiac and Cerebrovascular Events (MACCE). A retrospective cohort study was conducted analyzing the association between HZ and MACCE. We compared HZ patients...
Source: Herpes - February 9, 2023 Category: Infectious Diseases Authors: Amir Horev Anat Horev Adi Gordon-Irshai Michal Gordon Nicolas Andre Gal Ifergane Source Type: research
Vaccination, Acute Myocardial Infarction, and Ischemic Stroke After COVID-19 Infection
To the Editor We would like to highlight some key points about the recent article that reported that patients who received full vaccination against COVID-19 had a reduced risk of acute myocardial infarction (AMI) and ischemic stroke after COVID-19 diagnosis.
Source: JAMA - February 7, 2023 Category: General Medicine Source Type: research
Vaccination, Acute Myocardial Infarction, and Ischemic Stroke After COVID-19 Infection —Reply
In Reply We thank Dr Chu and colleagues for their comments about our Research Letter. Our analysis found that 2 doses of COVID-19 vaccine were associated with a reduced risk of AMI and ischemic stroke after COVID-19, using inverse probability treatment weighting to mitigate the imbalance in patient characteristics by vaccination status.
Source: JAMA - February 7, 2023 Category: General Medicine Source Type: research
The U.S. Still Doesn ’ t Have Good COVID-19 Data. Here ’ s Why That ’ s a Problem
Check the COVID-19 Data Tracker from the U.S. Centers for Disease Control and Prevention (CDC), and you’ll get a rundown of the latest case numbers, hospitalizations, and deaths. Those categories might seem straightforward, but the data, say many experts, are telling us a lot less than we think they are.
That’s because it’s getting increasingly difficult to parse who is hospitalized or dies from COVID-19, and who is hospitalized or dies from another reason but with COVID-19. Across the U.S., “COVID-19 hospitalizations” represent all kinds of patients: those who need hospital-level care for sev...
Source: TIME: Health - January 30, 2023 Category: Consumer Health News Authors: Alice Park Tags: Uncategorized COVID-19 healthscienceclimate Source Type: news
Real-World Study Confirms Benefit of XARELTO ® (rivaroxaban) for Secondary Prevention of Venous Thromboembolism in Cancer Patients
TITUSVILLE, NJ, December 9, 2022 – The Janssen Pharmaceutical Companies of Johnson & Johnson today announced observational data from eight years of clinical practice showing that the oral Factor Xa inhibitor XARELTO® (rivaroxaban) is associated with comparable effectiveness and safety to the Factor Xa inhibitor apixaban for the treatment of cancer-associated thromboembolism (CAT) in a broad cohort of patients with various cancer types. Patients with CAT are at a higher risk of venous thromboembolism (VTE), which is the second-leading cause of death in people with cancer.1Data from the Observational Study in Cancer-A...
Source: Johnson and Johnson - December 9, 2022 Category: Pharmaceuticals Tags: Latest News Source Type: news
Risk of, and risk factors for, vasculopathy associated with acute herpes zoster
We aimed to summarize the known risk of vasculopathy (stroke, myocardial infarction [MI], and transient ischemic attack [TIA]) after herpes zoster (HZ) and the impact of antiviral treatment and vaccination against HZ on the risk of vasculopathy.
Source: Journal of Stroke and Cerebrovascular Diseases - December 3, 2022 Category: Neurology Authors: Barbara P. Yawn, Alistair C. Lindsay, Mitra Yousefi, Chengbin Wang Source Type: research
Background rates of adverse events of special interest for COVID-19 vaccine safety monitoring in the United States, 2019-2020
CONCLUSION: AESI background rates varied by database and demographics and fluctuated in March-December 2020, but most returned to pre-pandemic levels after May 2020. It is critical to standardize demographics and consider seasonal and other trends when comparing historical rates with post-vaccination AESI rates in the same database to evaluate COVID-19 vaccine safety.PMID:36404170 | DOI:10.1016/j.vaccine.2022.11.003
Source: Vaccine - November 20, 2022 Category: Allergy & Immunology Authors: Keran Moll Bradley Lufkin Kathryn R Fingar Cindy Ke Zhou Ellen Tworkoski Chianti Shi Shayan Hobbi Mao Hu Minya Sheng Jillian McCarty Shanlai Shangguan Timothy Burrell Yoganand Chillarige Jeff Beers Patrick Saunders-Hastings Stella Muthuri Kathryn Edwards Source Type: research
A post-marketing safety assessment of COVID-19 mRNA vaccination for serious adverse outcomes using administrative claims data linked with vaccination registry in a city of Japan
CONCLUSION: The findings suggested that the COVID-19 mRNA vaccine was generally safe, whilst a signal of pulmonary embolism following the first dose of the COVID-19 mRNA vaccine was observed.PMID:36371366 | DOI:10.1016/j.vaccine.2022.10.088
Source: Vaccine - November 12, 2022 Category: Allergy & Immunology Authors: Yoshinori Takeuchi Masao Iwagami Sachiko Ono Nobuaki Michihata Kohei Uemura Hideo Yasunaga Source Type: research
